Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study of AZD1775, a Wee1 Inhibitor, in Patients With CCNE1 Amplification

Trial Profile

A Phase 2 Study of AZD1775, a Wee1 Inhibitor, in Patients With CCNE1 Amplification

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adavosertib (Primary)
  • Indications Advanced breast cancer; Carcinoma; Cholangiocarcinoma; Endometrial cancer; Gallbladder cancer; Germ cell and embryonal neoplasms; Germ cell cancer; Malignant melanoma; Oesophageal cancer; Ovarian cancer; Prostate cancer; Sarcoma; Solid tumours; Urogenital cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Mar 2023 Status changed from suspended to completed.
    • 05 Dec 2022 Results (n=30) assess the antitumor activity of adavosertib in patients with CCNE1-amplified, advanced refractory solid tumors published in the Journal of Clinical Oncology
    • 01 Oct 2022 Planned End Date changed from 30 Sep 2022 to 30 Sep 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top